Simani Gaseitsiwe

SANTHE Collaborative Grant Awardee,
SANTHE Consortium Steering Committee Member,
SANTHE Scientific Innovation Awardee,
SANTHE Site Principal Investigator

Botswana Harvard Health Partnership (BHP) Gaborone, Botswana


Antibody and T-Cell responses elicited by different SARS-CoV-2 vaccines in Botswana: durability and impact of HIV infection and previous SARS-CoV-2 and prevalent infection

Collaboration Interests
  • Antimicrobial resistance
  • HIV diversity
  • Mycobacterium tuberculosis (Mtb) molecular epidemiology
  • Viral hepatitis

Simani Gaseitsiwe works as a Research Associate at BHP. His work focuses on infection biology, aiming to understand how different pathogens interact with the human host. His primary pathogen of interest is HIV and his research on HIV focuses on understanding its diversity and how HIV-1 subtype C responds to antiretroviral therapy (ART) especially the resistance mutations that develop in response to different antiretrovirals. This work has helped optimise HIV treatment and better monitor treatment outcomes in HIV-1C infection. Other pathogens of interest in his research group include hepatitis B virus, Mycobacterium tuberculosis (Mtb), and SARS CoV-2. For these pathogens, Gaseitsiwe’s groups interest has been in understanding the molecular epidemiology of these pathogens in Botswana and how they interact with HIV.

SANTHE is an Africa Health Research Institute (AHRI) flagship programme funded by the Science for Africa Foundation through the DELTAS Africa programme; the Bill & Melinda Gates Foundation; Gilead Sciences Inc.; and the Ragon Institute of Mass General, MIT, and Harvard.